Novel anti-IGF-IR antibodies and uses thereof

• US 20080193445A1
• Filed: 05/08/2007
• Published: 08/14/2008
• Est. Priority Date: 01/18/2002
• Status: Abandoned Application

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.), Institut De Recherche Pierre Fabre (Pierre Fabre Participations SAS)
• Original Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Inventors: Leger, Olivier, Corvaia, Nathalie, Chastain, Michael, Goetsch, Liliane, Kuklin, Nelly
• Application Number:
  US11/801,080
• Publication Number:
  US 20080193445A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 47/6803 Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• CPC Class Codes: A61K 47/6805 the drug being a vinca alkaloid
• CPC Class Codes: A61K 47/6807 the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
• CPC Class Codes: A61K 47/6809 Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
• CPC Class Codes: A61K 47/6819 Plant toxins
• CPC Class Codes: A61K 47/6847 the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
• CPC Class Codes: A61K 47/6913 the liposome being modified on its surface by an antibody
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

Claims

1-54. -54. (canceled)

55. A method for the treatment or prevention of an oncogenic disorder characterized by cells expressing aberrant levels of IGF-1R relative to normal, said method comprising administering to the patient a therapeutically effective amount of a humanized anti-IGF-IR specific antibody or antigen-binding fragment thereof effective in treating said disorder, wherein

(a) said oncogenic disorder is selected from the group consisting of, ovarian cancer, colon cancer, pancreatic cancer, breast cancer, and prostate cancer, and

(b) wherein said IGF-1R antibody or antigen-binding fragment comprises a light chain complementarity determining region (CDR) selected from the group consisting of SEQ ID Nos. 2. 4 and 6 or at least one CDR having at least 95% sequence identity with one or more of SEQ ID Nos 2, 4 or 6 and a heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID Nos. 8, 10 and 12 or at least one CDR having at least 95% sequence identity with one or more of SEQ ID Nos 8. 10 or 12, wherein said antibody, or binding fragment thereof, binds to human insulin-like growth factor I receptor (IGF-IR) and inhibits binding of IGF1 and/or IGF2 to said IGF-IR

56. The method according to claim 55, wherein the heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs. 8, 10 or 12 and the light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs. 2, 4 or 6.

57. The method according to claim 55, wherein said humanized antibody, or one of its functional fragments, comprises a light chain comprising the amino acid sequence selected from the group consisting of SEQ ID No. 61 or 65, or a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs.:

75, 79 or 83.

59. The method according to claim 55, further comprising administering to said subject said humanized antibody in combination with an additional cancer therapeutic agent.

60. The method according to claim 55, wherein said additional cancer therapeutic agent is selected from the group consisting of tumor irradiation or a chemotherapeutic agent.

61. The method according to claim 60, wherein said additional chemotherapeutic agent is an agent selected from the group consisting of a corticosteroid, anti-emetic, cancer vaccine, analgesic, anti-vascular agent, cytokines, non-specific immunostimulant and anti-proliferative agent.

62. The method according to claim 60, wherein said comprises a DNA damaging agent selected from the group consisting of verapamil, podophyllotoxin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, cisplatin, carboplatin, oxaliplatin, and combinations thereof.

63. The method of claim 60, wherein said irradiation is selected from the group consisting of X-ray radiation, UV-radiation, γ

-radiation, microwave radiation, and combinations thereof, further comprising administering to said mammal said antibody in combination with an agent selected from the group consisting of a corticosteroid, anti-emetic, cancer vaccine, analgesic, anti-vascular agent, and anti-proliferative agent.

64. The method according to claim 55, further comprising administering to said subject said humanized antibody in combination with an anti-emetic agent, wherein said agent is selected from the group consisting of ondansetron hydrochloride, granisetron hydrochloride, metroclopramide, domperidone, haloperidol, cyclizine, lorazepam, prochlorperazine, dexamethasone, levomepromazine, or tropisetron.

65. The method according to claim 55, further comprising administering said antibody in combination with an analgesic agent, wherein said agent is selected from the group consisting of ibuprofen, naproxen, choline magnesium trisalicylate, or oxycodone hydrochloride.

66. The method according to claim 55, further comprising administering said humanized antibody in combination with an anti-proliferative agent, wherein said agent is selected from the group consisting of farnesyl protein transferase inhibitors, .alpha.v.beta.3 inhibitors, alpha.v.beta.5 inhibitors, p53 inhibitors, VEGF inhibitors, VEGFR inhibitors, EGFR inhibitors and Her2neu inhibitors or heterodimers thereof, and PDGFR inhibitors.

58. A method of assaying a subject for an IGF-1R mediated oncogenic disorder, comprising:

a) obtaining a test sample of cells derived from said subject;

b) assaying said test sample to determine the amount of expression of IGF-1R that is present on a surface of said cells;

c) comparing the amount of IGF-1R expression determined in step b) with the amount of IGF-1R expression in a control sample of cells; and

d) determining if said subject is at increased risk of having or developing said IGF-1R mediated disorder based upon the comparison of step c), wherein said oncogenic disorder is selected from the group consisting of, ovarian cancer, colon cancer, pancreatic cancer, breast cancer, and prostate cancer.

67. (canceled)

68. A method for the treatment or prevention of an oncogenic disorder characterized by cells expressing high levels of IGF-1R relative to normal, said method comprising administering to the patient a therapeutically effective amount of a humanized anti-IGF-1R specific antibody or antigen-binding fragment thereof effective in treating said disorder, wherein

(a) said oncogenic disorder is selected from the group consisting of neuroblastoma, rhabdomyosarcoma, osteosarcoma, pediatric cancer, Wilm'"'"'s cancer and Ewing Sarcoma, and

(b) wherein said IGF-1R antibody or antigen-binding fragment comprises a light chain complementarity determining region (CDR) selected from the group consisting of SEQ ID Nos. 2, 4 and 6 or at least one CDR having at least 95% sequence identity with one or more of SEQ ID Nos 2, 4 or 6 and a heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID Nos. 8, 10 and 12 or at least one CDR having at least 95% sequence identity with one or more of SEQ ID Nos 8, 10 or 12, wherein said antibody, or binding fragment thereof, binds to human insulin-like growth factor I receptor (IGF-IR) and inhibits binding of IGF1 and/or IGF2 to said IGF-IR.

69. The method according to claim 68, further comprising administering to said subject said humanized antibody in combination with an additional cancer therapeutic agent.

70. The method according to claim 69, wherein said additional cancer therapeutic agent is selected from the group consisting of tumor irradiation or a chemotherapeutic agent.

71. The method according to claim 70, wherein said additional chemotherapeutic agent is an agent selected from the group consisting of a corticosteroid, anti-emetic, cancer vaccine, analgesic, anti-vascular agent, cytokines, non-specific immunostimulant and anti-proliferative agent.